Communiqués Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:22:46 30/06/2026			Varia. 5j.	Varia. 1 janv.
247,16 ^USD	+2,50 %		+1,77 %	+34,83 %

26/06	Axsome Therapeutics lance l'essai de phase 3 FOCUS-3 sur le solriamfetol chez les adolescents souffrant de trouble du déficit de l'attention avec hyperactivité	CI
26/06	Axsome Therapeutics annonce l'administration de la première dose dans l'étude de phase 3 du solriamfetol contre le TDAH	MT

Communiqués

26/06	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)	GL
18/06	Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month	GL
15/06	Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026	GL
05/06	Axsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society 68th Annual Scientific Meeting	AQ
04/06	Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting	GL
03/06	Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation	GL
01/06	Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month	GL
27/05	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
26/05	Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting	GL
26/05	Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting	AQ
07/05	Axsome Therapeutics Recognizes Mental Health Month	GL
07/05	Axsome Therapeutics Recognizes Mental Health Month	AQ
05/05	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
04/05	Axsome: Q1 Earnings Snapshot	AQ
04/05	Axsome Therapeutics : First Quarter 2026 Corporate Presentation	PU
04/05	Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	GL
01/05	Axsome Therapeutics : AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call Presentation	PU
01/05	Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader	GL
30/04	Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease	GL
08/04	Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4	GL
08/04	Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4	AQ
01/04	Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions	GL
01/04	Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions	AQ
12/03	Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)	AQ
25/02	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL